Published in Eur J Endocrinol on December 10, 2012
Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab (2013) 1.45
Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab (2013) 0.93
Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage. Eur J Endocrinol (2013) 0.78
Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study. J Neurol Neurosurg Psychiatry (2014) 0.77
Hypopituitarism after subarachnoid haemorrhage, do we know enough? BMC Neurol (2014) 0.76
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev (2004) 3.79
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Hypopituitarism. Lancet (2007) 2.27
Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care (2013) 1.98
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA (2007) 1.59
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Endocrine function is altered in chronic migraine patients with medication-overuse. Headache (2006) 1.47
The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens (2010) 1.46
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38
Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J (2004) 1.32
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2012) 1.32
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res (2009) 1.26
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. Proteomics (2007) 1.23
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes (2007) 1.22
Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab (2003) 1.12
Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab (2002) 1.11
Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol (2006) 1.10
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol (2010) 1.09
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab (2007) 1.06
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol (2004) 1.05
Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol (2012) 1.05
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. Obes Res (2002) 1.04
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) (2011) 1.02
The IGF system. Acta Diabetol (2010) 1.01
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) (2003) 1.01
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol (2004) 1.01
Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol (2010) 1.01
Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. Orthopedics (2013) 1.00
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol (2009) 1.00
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol (2006) 0.99
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol (2003) 0.98
Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum (2007) 0.98
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin Endocrinol (Oxf) (2003) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology (2008) 0.96
Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. Eur J Endocrinol (2007) 0.95
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. J Clin Endocrinol Metab (2004) 0.95
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab (2006) 0.95
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol (2007) 0.94
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab (2014) 0.94
Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics (2007) 0.94
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) (2011) 0.93
Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol (2007) 0.93
The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 0.93
Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology (2007) 0.92
Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology (2007) 0.92
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol (Oxf) (2004) 0.92
Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab (2014) 0.91
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol (2009) 0.91
Crystal structure of a spin-labeled, channel-forming alamethicin analogue. Angew Chem Int Ed Engl (2007) 0.91
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J (2012) 0.91
Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis? Proteomics Clin Appl (2010) 0.91
Association of craniopharyngioma and pituitary adenoma. Endocrine (2013) 0.88
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab (2002) 0.88
Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol (2010) 0.88
Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol (2002) 0.88
GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology (2013) 0.88
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab (2003) 0.88
Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab (2008) 0.87
An unusual cause of external snapping hip. J Radiol Case Rep (2011) 0.87
Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol (2003) 0.87
Corticotrope hypersecretion coupled with cortisol hypo-responsiveness to stimuli is present in patients with autoimmune endocrine diseases: evidence for subclinical primary hypoadrenalism? Eur J Endocrinol (2006) 0.87
Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology (2002) 0.87
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome. Pituitary (2004) 0.87
Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression. J Am Heart Assoc (2013) 0.86
The nutritional control of ghrelin secretion in humans: the effects of enteral vs. parenteral nutrition. Eur J Nutr (2006) 0.86
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. Eur J Endocrinol (2010) 0.86
Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol (2005) 0.86
The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) (2002) 0.85
GPR103b functions in the peripheral regulation of adipogenesis. Mol Endocrinol (2010) 0.85
Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. Rheumatology (Oxford) (2013) 0.85
Ghrelin and anterior pituitary function. Front Horm Res (2010) 0.85